This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
When the Food and Drug Administration issued a safety warning in 2022 about severe tooth decay associated with a commonly prescribed, orally dissolving opioid use disorder medication called buprenorphine, University of Florida researchers asked the question: How could scientists better measure the oral conditions that put teeth at risk?
Their efforts have culminated in the invention of GatorpH—a free, open-source software tool designed to help scientists analyze dynamic changes in oral pH and estimate factors associated with cavity risk.
The team, led by UF College of Dentistry D.M.D./Ph.D. program candidate Kyle Kasparian, is now poised to use GatorpH for its ultimate objective: reformulating a version of buprenorphine that retains its important therapeutic benefits but does not cause cavities.
"It [buprenorphine] will still be used to treat opioid use disorder," Kasparian said. "However, we are designing the formulation so that it won't have these associated cavity risks ... With more than 15 million prescriptions written for this medication each year, that will be a huge benefit."
Tooth decay begins within dental plaque, a sticky biofilm that traps bacterial acids against tooth enamel. Because plaque limits saliva's ability to neutralize those acids, acidity can remain at harmful levels long after the rest of the mouth returns to normal, leading to tooth mineral loss.
Accurately capturing what happens to pH over time presents researchers with a practical challenge.
Source link







